Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05637879 · ClinicalTrials.gov registry record · Phase 2
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
A Phase 2 study of PTSD, sponsored by White River Junction Veterans Affairs Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT05637879: Recruiting Phase 2 study of PTSD, sponsored by White River Junction Veterans Affairs Medical Center.
NCT05637879 is a Phase 2 study of PTSD that is actively recruiting participants, run by White River Junction Veterans Affairs Medical Center. The registered enrollment target is 92 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05637879, a Phase 2 study of PTSD, is actively recruiting participants, sponsored by White River Junction Veterans Affairs Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Primary Outcome
Queries the frequency and intensity of symptoms of post-traumatic stress disorder (PTSD). The score ranges from 0-80 with a higher score indicating worse symptoms. It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Glecaprevir/pibrentasvir
Study Locations (1)
Vermont
- White River Junction VAMC - White River Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What NCT05637879 shows while recruiting
NCT05637879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (69% lower).
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05637879 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT05637879 about?
NCT05637879 is a clinical study titled "Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder". A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infectio...
What is the current status of trial NCT05637879?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2023-12-18. Estimated completion is 2026-09-30.
What conditions does trial NCT05637879 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT05637879?
The interventions under investigation include: Placebo (OTHER), Glecaprevir/pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT05637879?
This trial is sponsored by White River Junction Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05637879 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05637879's enrollment target sits among peer trials
92 69th of 154 higher than 86 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
-
Intranasal Insulin for Posttraumatic Stress Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI